Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
Author:
Funder
National Institutes of Health
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference27 articles.
1. From hope to reality: durable overall survival with immune checkpoint inhibitors for advanced lung cancer;Rangachari;J Clin Oncol,2019
2. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 Study;Garon;J Clin Oncol,2019
3. Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?;Piper;Transl Lung Cancer Res,2019
4. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?;Renner;J Glob Oncol,2019
5. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody;Maher;J Clin Oncol,2019
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma;Cancer Immunology, Immunotherapy;2023-09-21
2. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment;The Lancet Oncology;2023-05
3. Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial;Lung Cancer;2023-04
4. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development;Journal of Pharmacokinetics and Pharmacodynamics;2023-03-04
5. Immune checkpoint inhibitors in cancer patients with COVID-19;Open Life Sciences;2023-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3